新大环内酯类抗生素solithromycin在Ⅲ期临床试验中获阳性结果

发布时间：2018-07-12 08:39

本文选题：solithromycin + Ⅲ期临床试验　；参考：《国际药学研究杂志》2015年02期

【摘要】：正Cempra制药公司宣布,其下一代大环内酯类抗生素solithromycin口服胶囊,在1项用于社区获得性细菌性肺炎(community acquired bacterial pneumonia,CABP)患者的全球多中心、双盲、阳性药对照的Ⅲ期临床试验中,与拜耳公司的莫西沙星相比,达到非劣效的主要及次要目标。这项Solitaire-Oral研究随机入选
[Abstract]:Cempra Pharmaceuticals has announced that its next generation of macrolide antibiotics, solithromycin, was orally administered in a phase III clinical trial for patients with community-acquired bacterial pneumonia (community acquired bacterial pneumoniae) in a phase III clinical trial with double-blind, positive drug control. Compared with moxifloxacin of Bayer, the primary and secondary goals of non-inferior effect are achieved. The Solitaire-Oral study was randomly selected
【分类号】：R969.4

【相似文献】